Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. (Nasdaq: NOVT) is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. As a trusted technology partner to medical and advanced technology equipment manufacturers, the company frequently features in news related to its financial performance, capital markets activity, and participation in investor and industry conferences.
News about Novanta often includes quarterly earnings releases and related conference call announcements, where the company reports GAAP results alongside non-GAAP metrics such as Adjusted EBITDA, Adjusted Diluted EPS, and Organic Revenue Growth. These updates provide insight into how its precision medicine, precision manufacturing, medical solutions, robotics and automation, and advanced surgery businesses are performing.
Investors can also expect coverage of capital structure developments, such as the offering and pricing of tangible equity units that combine prepaid stock purchase contracts with senior amortizing notes, as well as amendments to credit agreements and details of senior credit facilities. Announcements about share repurchase authorizations by the Board of Directors are another recurring news theme, reflecting decisions on capital allocation.
In addition, Novanta regularly appears in conference and investor event schedules, including healthcare and industrial conferences hosted by firms such as J.P. Morgan, Baird, Jefferies, and CJS Securities. These events highlight management’s engagement with the investment community and provide forums for discussing strategy and market positioning.
This news page aggregates such items in one place, helping readers follow Novanta’s earnings announcements, financing activities, share repurchase plans, and public presentations over time.
Novanta (NASDAQ: NOVT) joined the NVIDIA Halos AI Systems Inspection Lab, the first ANAB‑accredited inspection lab for AI-driven physical systems. Novanta will work with NVIDIA to validate interoperability of its motion control and sensing technologies with NVIDIA platforms, including NVIDIA IGX Thor.
This collaboration aims to streamline OEM integration, accelerate time‑to‑market for robotics, support system‑level certification, and align Novanta hardware and subsystems with NVIDIA software for warehouse automation, industrial robotics, and humanoid platforms.
Novanta (Nasdaq: NOVT) reported Q4 2025 GAAP revenue of $258.3M (+8.5% YoY) and GAAP diluted EPS of $0.45. Q4 Adjusted Diluted EPS rose 20% to $0.91 and Adjusted EBITDA rose 17% to $60.7M. Full‑year 2025 GAAP revenue was $980.6M; Adjusted Diluted EPS was $3.29.
The company ended 2025 with $381M cash, $251M debt (Net Debt: ($121M)), a 25% increase in customer bookings and a book‑to‑bill of 1.11x. 2026 guidance: revenue $1.03–1.05B, Adjusted EBITDA $245–250M.
Novanta (Nasdaq: NOVT) will release its fourth quarter 2025 results on Tuesday, February 24, 2026. The company will hold a conference call the same day at 8:00 a.m. ET to discuss results.
Investors can join by dialing (888) 346-3959 before the call or via a live webcast on the company’s Investors > Events & Presentations page at www.novanta.com. An audio replay will be posted about three hours after the call and will remain available through Monday, April 27, 2026.
Novanta (NASDAQ: NOVT) announced that Chuck Ravetto, Chief Operating Officer, will participate in the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026. The event is being held virtually, and the presentation will cover the company’s recent developments and outlook for investors.
Novanta (Nasdaq: NOVT) announced that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on Wednesday, January 14, 2026 in San Francisco, California.
The announcement identifies the presenters, date, and location but does not include presentation timing or webcast details.
Novanta (Nasdaq: NOVT) priced a public offering of 11,000,000 tangible equity units at $50.00 per unit, with an anticipated close on November 12, 2025 and a 30-day over-allotment for up to 1,650,000 additional units.
The units combine a prepaid stock purchase contract and a senior amortizing note due November 1, 2028; notes carry a 6.30% interest rate and quarterly installments. Settlement will deliver between 0.3729 and 0.4662 common shares per purchase contract. The threshold appreciation price is $134.0842 (~25% above the Nov 6, 2025 close).
Net proceeds are expected to be approximately $533.0 million (up to $613.2 million if over-allotment exercised). Novanta intends to use proceeds to strengthen the balance sheet, which may include repaying about $317 million of revolver debt and funding acquisitions, capex, share repurchases, working capital and other corporate purposes.
Novanta (Nasdaq: NOVT) announced a public offering of 11,000,000 tangible equity units with an aggregate stated amount of $550.0 million; each unit has a stated amount of $50.00 and comprises a prepaid stock purchase contract and a senior amortizing note due 2028. Novanta has applied to list the units on Nasdaq under NOVTU and granted underwriters a 30-day option to buy up to 1,650,000 additional units to cover over-allotments.
Net proceeds are expected to be used to strengthen the balance sheet and enhance strategic flexibility, including a planned repayment of approximately $317 million under the revolving credit facility and for working capital, acquisitions, capex, share repurchases and general corporate purposes.
Novanta (Nasdaq: NOVT) reported Q3 2025 results on November 3, 2025: GAAP revenue $247.8M (+1.4% YoY) and GAAP net income $10.7M with GAAP diluted EPS $0.30. Non-GAAP results included Adjusted EBITDA $58.1M and Adjusted diluted EPS $0.87. Bookings grew 17% YoY with book-to-bill of 1.03x. Q3 operating cash flow was $8.5M, down from $23.0M a year earlier. For Q4 2025 Novanta expects revenue of $253M–$257M; full-year 2025 revenue guidance is $975M–$979M. The company reiterated product-driven growth and provided 2026 mid-single-digit organic growth expectations.
Novanta (Nasdaq: NOVT) announced that Matthijs Glastra, Chair & Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 in London.
The presentation provides an investor-facing update and a scheduled public appearance by senior management at a major healthcare investor conference.
Novanta (Nasdaq: NOVT) will host an ISO working group event on humanoid robot safety standards in Barcelona, Spain, from October 27–30, 2025. The multi-year ISO initiative aims to define a global safety framework for designing, developing, and deploying humanoid robots, including safe human/robot interaction in real-world environments.
The session will gather 40–50 international experts to advance the proposed international standard ISO 25785-1. Hosting the event highlights Novanta's stated commitment to collaborative innovation and advancing safety-first practices for physical AI and humanoid robotics.